RedHill Biopharma wins Nasdaq extension to regain $1 minimum bid compliance by April 5, 2027
RDHL•RedHill Biopharma received an extension until April 5, 2027, to regain Nasdaq’s $1.00 minimum bid compliance; its ADSs remain listed and trading on the Nasdaq Capital Market.
1. Compliance extension
Nasdaq extended RedHill Biopharma’s deadline to regain compliance with its $1.00 minimum bid price rule to April 5, 2027, after an initial compliance period ended October 5, 2026. Nasdaq will close the matter if the ADS bid price is at or above $1.00 for 10 consecutive business days. The notice does not immediately affect the ADS listing or trading on the Nasdaq Capital Market.
